Quchang Ouyang
- Oncology top 10%
- HER2/EGFR in Cancer Research 22
- Cancer Treatment and Pharmacology 13
- Lung Cancer Research Studies 7
- Peptidase Inhibition and Analysis 5
-
- Advanced Breast Cancer Therapies 28
-
- Breast Cancer Treatment Studies 8
-
- Chronic Lymphocytic Leukemia Research 5
- Estrogen and related hormone effects 5
- Journals
- Nature Communications (1 paper)Journal of Clinical Oncology (14 papers)SHILAP Revista de lepidopterología (1 paper)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Quchang Ouyang
42 papers receiving 358 citations
Hit Papers
Peers
Comparison fields: 5 of 49
- Oncology 270
- Pulmonary and Respiratory Medicine 151
- Cancer Research 69
- Genetics 35
- Radiology, Nuclear Medicine and Imaging 59
Countries citing papers authored by Quchang Ouyang
This map shows the geographic impact of Quchang Ouyang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Quchang Ouyang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Quchang Ouyang more than expected).
Fields of papers citing papers by Quchang Ouyang
This network shows the impact of papers produced by Quchang Ouyang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Quchang Ouyang. The network helps show where Quchang Ouyang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Quchang Ouyang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 3 | |
| 7 | The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trialbreakdown → | 2024 | 45 |
| 8 | 2023 | 7 | |
| 9 | 2023 | 5 | |
| 10 | 2023 | 1 | |
| 11 | 2023 | 1 | |
| 12 | 2023 | 1 | |
| 13 | 2023 | 0 | |
| 14 | 2023 | 18 | |
| 15 | 2023 | 23 | |
| 16 | 2022 | 24 | |
| 17 | 2022 | 24 | |
| 18 | 2022 | 1 | |
| 19 | 2021 | 1 | |
| 20 | 2013 | 10 |
About Quchang Ouyang
Quchang Ouyang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 52 papers that have together received 363 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (28 papers), HER2/EGFR in Cancer Research (22 papers), Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (8 papers), Lung Cancer Research Studies (7 papers), Chronic Lymphocytic Leukemia Research (5 papers), Estrogen and related hormone effects (5 papers) and Peptidase Inhibition and Analysis (5 papers). The work is most often cited by research in Oncology (270 citations), Pulmonary and Respiratory Medicine (151 citations) and Cancer Research (69 citations). Quchang Ouyang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Binghe Xu, Qingyuan Zhang, Zhongsheng Tong, Tao Sun, Tao Sun, Yiqun Han, Xichun Hu, Xiaoyu Zhu, Xiaojia Wang and Jifeng Feng. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.